Cited by 1,417Iron Metabolism and DisordersErythropoietin and Anemia TreatmentFerroptosis and cancer prognosis

Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein

Open access
Nemeth, Elizabeta, Valore, Erika V., Territo, Mary, Schiller, Gary, Lichtenstein, Alan, Ganz, Tomas·2003·Blood

Abstract

Hepcidin is a liver-made peptide proposed to be a central regulator of intestinal iron absorption and iron recycling by macrophages. In animal models, hepcidin is induced by inflammation and iron loading, but its regulation in humans has not been studied. We report that urinary excretion of hepcidin was greatly increased in patients with iron overload, infections, or inflammatory diseases. Hepcidin excretion correlated well with serum ferritin levels, which are regulated by similar pathologic stimuli. In vitro iron loading of primary human hepatocytes, however, unexpectedly down-regulated hepcidin mRNA, suggesting that in vivo regulation of hepcidin expression by iron stores involves complex indirect effects. Hepcidin mRNA was dramatically induced by interleukin-6 (IL-6) in vitro, but not by IL-1 or tumor necrosis factor α (TNF-α), demonstrating that human hepcidin is a type II acute-phase reactant. The linkage of hepcidin induction to inflammation in humans supports its proposed role as a key mediator of anemia of inflammation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2002-10-3235

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Cytokines such as interleukin (IL)-1, IL-6, or IL-22 as well as bacterial LPS or endoplasmic reticulum stress induce the formation of hepcidin in the liver.

    “Cytokines such as interleukin (IL)-1, IL-6, or IL-22 as well as bacterial LPS or endoplasmic reticulum stress induce the formation of the master regulator of iron homeostasis, hepcidin, in the liver (Nemeth et al., 2003; Vecchi et al., 2009; Armitage et al., 2011).”

    From Iron at the interface of immunity and infection (2014) · cites this paper as Nemeth et al., 2003

    The Results and discussion section (page not supplied) reports strong hepcidin mRNA induction by IL-6 in human hepatocytes and a small increase with LPS alone. It reports IL-1 induction only after 24 hours, probably indirectly through IL-6; the copy does not address IL-22 or endoplasmic reticulum stress. Thus, this source supports some, but not all, of the factors listed in the jointly cited sentence. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Patients with anemia of inflammation due to inflammatory disorders or infections have markedly increased excretion of urinary hepcidin.

    “patients with AI due to inflammatory disorders or infections had markedly increased excretion of urinary hepcidin”
  • IL-6 strongly induces hepcidin mRNA in fresh human hepatocytes.

    “strong induction of hepcidin mRNA by IL-6”
  • IL-1α and TNFα do not strongly induce hepcidin mRNA in fresh human hepatocytes.

    “but not IL-1 α or TNFα”
  • Hepcidin production is diminished in the most common form of hemochromatosis caused by mutations in the HFE gene.

    “in the most common form of hemochromatosis, that caused by mutations in the HFE gene”

    From IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin (2004) · cites this paper as [12]

    The Results and discussion (page unavailable) compare urinary hepcidin in patients with well-controlled hereditary hemochromatosis with levels in patients with anemia of inflammation, but do not say hepcidin production is diminished relative to healthy people. A search for HFE mutations found no passage identifying the hemochromatosis patients as having HFE-related disease. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 6

  1. Fleming RE, Sly WS. Hepcidin: a putative iron- regulatory hormone relevant to hereditary hemo- chromatosis and the anemia of chronic disease. Proc Natl Acad Sci U S A. 2001;98:8160-8162.
  2. Nicolas G, Bennoun M, Devaux I, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A. 2001; 98:8780-8785.
  3. Nicolas G, Bennoun M, Porteu A, et al. Severe iron deficiency anemia in transgenic mice ex- pressing liver hepcidin. Proc Natl Acad Sci U S A. 2002;99:4596-4601.
  4. Shike H, Lauth X, Westerman ME, et al. Bass hepcidin is a novel antimicrobial peptide induced by bacterial challenge. Eur J Biochem. 2002;269: 2232-2237.
  5. Hunter HN, Fulton DB, Ganz T, Vogel HJ. The solution structure of human hepcidin, a peptide- hormone with antimicrobial activity that is in- volved in iron uptake and hereditary hemochro- matosis. J Biol Chem. 2002;277:37597-37603.
  6. Moshage H. Cytokines and the hepatic acute phase response. J Pathol. 1997;181:257-266.

Cited by

Sorted by citations

Authors
Nemeth, E., Valore, E. V., Territo, M., Schiller, G., Lichtenstein, A., & Ganz, T.
Affiliations
University of California, Los Angeles (US)
Venue
Blood
Published
2003-04-01
Volume
101
Issue
7
Pages
2461-2463
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2059080581
Cited by
1,417
References
6
Citations by year
2026: 16 · 2025: 31 · 2024: 27 · 2023: 44 · 2022: 41 · 2021: 61 · 2020: 54 · 2019: 56 · 2018: 45 · 2017: 56 · 2016: 51 · 2015: 66 · 2014: 85 · 2013: 82 · 2012: 68
FWCI
35.83
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
  • Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Ferroptosis and cancer prognosis
Keywords
hepcidin, anemia of chronic disease, acute phase proteins, iron overload, iron absorption, iron recycling, serum ferritin, interleukin-6, hepatocytes, inflammation, iron stores
MeSH terms
Acute-Phase Proteins, Anemia, Ferritins, Humans, Infections, Inflammation, Interleukin-1, Iron, RNA, Messenger, Tumor Necrosis Factor-alpha, Interleukin-6, Case-Control Studies, Iron Overload, Hepatocytes, Antimicrobial Cationic Peptides, Hepcidins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review